MannKind reports Q1 EPS 7c vs 6c last year

Reports Q1 revenue $78.354M, consensus $75.86M. “The first quarter was marked by strong year-over-year NRx growth in Afrezza, substantial Tyvaso DPI-related revenues and continued progress in our Phase 3 trial of MNKD-101 in NTM lung disease,” said Michael Castagna, PharmD, Chief Executive Officer of MannKind (MNKD) Corporation. “We expect to file for approval of Afrezza in the pediatric population this summer and to continue developing our MNKD-201 program in IPF.”